I think that the poster titled 'Assessment of the anti-inflammatory effects of cannabidiol and its fluorinated derivative in in vitro and in vivo models of atopic dermatitis', could actually be of PHYTECS, whose management will nonetheless shortly find out that, in this race, Botanix has already left the blocks. They are still testing it on mouses while BOT is about to release its data for BTX1204's phase 1b trial.
Nobody does it better
Makes me feel sad for the rest
Nobody does it half as good as you
BOT, you're the best
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)